M. Oh

Haemophilia B: Where are we now and what does the future hold?

Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects

Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database

Systemic sclerosis

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma

Aptamers as targeted therapeutics: current potential and challenges

Prophylaxis in the haemophilia population

Guidelines for the management of hemophilia

Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoring

Differences in presentation of younger and older systemic sclerosis patients in clinical trials.